

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kindstar Globalgene Technology, Inc.**  
**康聖環球基因技術有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 9960)**

**DISCLOSEABLE TRANSACTION – COMPLETION OF ACQUISITION OF EQUITY INTEREST IN THE TARGET COMPANIES**

References are made to the announcements of Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated September 20, 2024 and October 8, 2024 (the “**Announcements**”) in relation to, among other things, the discloseable transactions (collectively, the “**Acquisitions**”) of (i) the transfer of 100% equity interest in the Target WFOE to Kindstar Wuhan WFOE conditionally agreed by AnchorDx HK and the Target WFOE Domestic Sellers; and (ii) the transfer of 100% equity interest in the Target US Company to the Company conditionally agreed by AnchorDx HK. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

**Completion of the Acquisitions**

The Board is pleased to announce that as the Conditions Precedent of the Acquisitions have been satisfied/appropriately waived, on January 24, 2025 (the “**Completion Date**”), the Acquisitions have been completed pursuant to the Transaction Agreement, the Amendment Agreement (as described below) and, if applicable, the relevant specific transfer agreement/document whereby (i) 100% equity interest in the Target WFOE has been transferred to Kindstar Wuhan WFOE, and (ii) 49% equity interest in the Target US Company has been transferred to the Company (as described below).

In accordance with IFRS and the Group’s accounting policies, the financial results of the Target WFOE and the Target VIE Group Entities are consolidated with the financial results of the Group with effect from the Completion Date.

In view of the Completion of the Acquisitions on the Completion Date, the cash consideration will be paid by Kindstar Wuhan WFOE pursuant to the Transaction Agreement, please refer to the announcement of the Company dated September 20, 2024 for details of the arrangement.

## Issuance and Allotment of Consideration Shares to Wuxi Anchor and OrbiMed under the General Mandate

In view of the Completion of the Acquisitions on the Completion Date, on January 24, 2025, the Company issued 15,869,521 Shares to Wuxi Anchor and 43,561,835 Shares to OrbiMed in accordance with the Transaction Agreement at the Consideration Share Price of HK\$1.42 per Share.

The following table sets out the shareholding structure of the Company (i) immediately before the issuance of the Consideration Shares; and (ii) immediately after the issuance of the Consideration Shares:

Name of Shareholder	Immediately before the issuance of the Consideration Shares		Immediately after the issuance of the Consideration Shares	
	Number of Shares	Approximate % of total number of issued Shares	Number of Shares	Approximate % of total number of issued Shares
<b>Directors</b>				
Dr. HUANG (Notes 2, 3 & 4)	146,425,868	14.92	146,425,868	14.07
Mr. TU (Note 5)	64,361,864	6.56	64,361,864	6.18
Ms. CHAI Haijie	10,166,456	1.04	10,166,456	0.98
Mr. HUANG Zuie-Chin (Note 6)	73,119,632	7.45	73,119,632	7.03
<b>Substantial Shareholders (excluding Directors)</b>				
Ms. GUO Gui-Rong (Notes 3 & 4)	146,425,868	14.92	146,425,868	14.07
Mr. HUANG Bo (Notes 2 & 7)	99,299,404	10.12	99,299,404	9.54
<b>Public Shareholders</b>				
Wuxi Anchor	–	–	15,869,521	1.52
OrbiMed	–	–	43,561,835	4.19
Others	441,492,848	44.99	441,492,848	42.42
<b>Total</b>	<b>981,291,940</b>	<b>100.00</b>	<b>1,040,723,296</b>	<b>100.00</b>

Notes:

- (1) As at the date of this announcement, the Company has 1,040,723,296 Shares in issue, including 7,064,000 treasury shares held by the Company.

- (2) *Perfect Tactic Group Limited (“Perfect Tactic”) is a company incorporated in the British Virgin Island held as to 99.8% and 0.2% by Infinite Prosperity Holdings LLC (“Infinite Prosperity”) and Kindstar Rui An Medical Technology Company Limited (康聖瑞安醫學技術有限公司) (“Kindstar Rui An”), respectively. Infinite Prosperity is wholly owned by Jackson Hole Trust Company (“Jackson Hole”), the trustee to the Shiang Huang Family Trust which was established by Dr. HUANG as settlor. Kindstar Rui An is indirectly wholly owned by Dr. Huang. Accordingly, Dr. HUANG is deemed to be interested in the total number of Shares held by Perfect Tactic.*

*The Shiang Huang Family Trust is a discretionary trust and the beneficiaries of which include Dr. HUANG and his family members who are his associates, and their lineal descendants. Under the trust deed of the Shiang Huang Family Trust, for so long as the Jackson Hole holds or controls any shares in Perfect Tactic, all voting rights with respect to investment decisions attaching thereto will be exercised by Mr. HUANG Bo as investment advisor to the Shiang Huang Family Trust. Accordingly, each of Infinite Prosperity, Jackson Hole, Mr. HUANG Bo and Dr. HUANG is deemed to be interested in the total number of Shares held by Perfect Tactic.*

- (3) *Each of Dr. HUANG and Ms. GUO Gui-Rong, being the spouse of the other person, is deemed to be interested in the total number of Shares the other person holds or is interested in.*
- (4) *According to the voting proxy arrangements dated April 28, 2021, January 1, 2017 and November 2, 2020, Ms. GUO Gui-Rong has effective control over the voting rights attached to the Shares held by each of Perfect Tactic, Mr. CHEN Zhong (“Mr. CHEN”) and Ever Prospect Global Limited (“Ever Prospect”), which is wholly owned by Mr. TU. Accordingly, Ms. GUO Gui-Rong is deemed to be interested in (i) the 48,361,508 Shares held by Perfect Tactic, (ii) 3,468,800 Shares held by Mr. CHEN, and (iii) 38,624,144 Shares held by Ever Prospect. Dr. HUANG, being the spouse of Ms. GUO Gui-Rong, is deemed to be interested in the total number of Shares Ms. GUO Gui-Rong holds or is interested in.*
- (5) *Ever Prospect is wholly owned by Mr. TU. Accordingly, Mr. TU is deemed to be interested in the 38,624,144 Shares held by Ever Prospect. According to the voting proxy arrangement dated November 2, 2020, Ms. GUO Gui-Rong has effective control over the voting rights attached to the Shares held by Ever Prospect.*
- (6) *The general partner of Ningbo Meishan Bonded Port Zone Xinyue Kangsheng Equity Investment Limited Liability Partnership (寧波梅山保稅港區新岳康聖股權投資合夥企業(有限合夥)) (“Ningbo Xinyue”) is Ningbo Meishan Bonded Port Zone Ruixi Equity Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區瑞義股權投資管理合夥企業(有限合夥)) (“Ningbo Ruixi”), while the general partner of Wuhan Ruifu Medical Health Equity Investment Limited Liability Partnership (武漢瑞伏醫療健康股權投資合夥企業(有限合夥)) (“Wuhan Ruifu”) is Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd. (寧波梅山保稅港區瑞伏博健投資管理有限公司) (“Ningbo Ruifu”). The general partner of Ningbo Ruixi is Ningbo Ruifu. Accordingly, Ningbo Ruifu is deemed to be interested in the 41,829,140 Shares held by Wuhan Ruifu and the 30,710,492 Shares held by Ningbo Xinyue. Ningbo Ruifu is ultimately controlled by Mr. HUANG Zuie-Chin. Accordingly, Mr. HUANG Zuie-Chin is deemed to be interested in (i) the 41,829,140 Shares held by Wuhan Ruifu, and (ii) the 30,710,492 Shares held by Ningbo Xinyue.*
- (7) *Jackson Hole is the trustee of the Gui-Rong Guo Trust, a family trust established by Ms. GUO (as the settlor) with her and her family members being the beneficiaries. Under the trust deed of the Gui-Rong Guo Trust, for so long as the Jackson Hole holds or controls any Shares, all voting rights attaching to such Shares shall be in effect exercised by Mr. HUANG Bo, Dr. HUANG and Ms. GUO Gui-Rong’s son, as investment advisor to the Gui-Rong Guo Trust. Accordingly, each of Ms. GUO Gui-Rong and Mr. HUANG Bo is deemed to be interested in the total number of Shares held by Jackson Hole.*

## SHAREHOLDING STRUCTURE OF THE TARGET WFOE BEFORE AND AFTER THE COMPLETION

Details on the shareholding structure of the Target WFOE (i) immediately before the Completion and (ii) immediately after the Completion are as follows:

Name of Shareholder	Shareholding in the Target WFOE immediately before the Completion		Shareholding in the Target WFOE immediately after the Completion	
	Capital contribution	Shareholding <sup>(Note)</sup>	Capital contribution	Shareholding
	(US\$)	(%)	(US\$)	(%)
Kindstar Wuhan WFOE	–	–	21,235,467.41	100.00
<b>The Sellers</b>				
AnchorDx HK <sup>(Note)</sup>	18,628,203.41	87.72	–	–
Guangzhou KingMed	213,220.00	1.00	–	–
Suzhou Frontline BioVentures	632,043.00	2.98	–	–
Suzhou 6Dimensions	632,043.00	2.98	–	–
Suzhou Serica Jianxin	295,535.00	1.39	–	–
WuXi App	319,829.00	1.51	–	–
Zhong Jianxin	514,594.00	2.42	–	–
<b>Total</b>	<u>21,235,467.41</u>	<u>100.00</u>	<u>21,235,467.41</u>	<u>100.00</u>

*Note:* During the period from the date of the Transaction Agreement to immediately prior to the Completion, pursuant to certain debt-for-equity conversion arrangement, AnchorDx HK’s capital contribution to the Target WFOE has increased to US\$18,628,203.41 (representing approximately 87.72% equity interest in the Target WFOE), and the respective shareholding of each of the Target WFOE Domestic Sellers has reduced proportionally.

### Amendment Agreement to the Acquisitions

On January 24, 2025, the Company, Kindstar Wuhan WFOE, the Target WFOE, the Target US Company, AnchorDx Cayman, AnchorDx HK, the Target WFOE Domestic Sellers, Wuxi Anchor, OrbiMed, Jian-Bing FAN, the AnchorDx Cayman Preferred Shareholders (except Wuxi Anchor and OrbiMed) and Wing Shan TANG entered into an amendment agreement (the “**Amendment Agreement**”) to, among others, amend and supplement the acquisition arrangement of the Target US Company. To the best of the Directors’ knowledge, information and belief having made all reasonable enquiry, each of the parties to the Amendment Agreement (except the Company, Kindstar Wuhan WFOE, the Target WFOE and the Target US Company) and their respective ultimate beneficial owners is a third party independent of the Company and its connected persons.

Pursuant to the Amendment Agreement, the Company will acquire 49% equity interest in the Target US Company instead of 100% equity interest in the Target US Company. Accordingly, immediately after the Completion, the Target US Company will not become a subsidiary of the Company and AnchorDx HK will continue to hold 51% equity interest in the Target US Company (the “**Remaining Interests in the Target US Company**”). Pursuant to the Amendment Agreement, AnchorDx HK also granted the Company or its designated person an irrevocable and exclusive right to acquire all or part of the Remaining Interests in the Target US Company at nil consideration (by way of single or multiple transactions) at any time within three years after the Completion Date at the sole and absolute discretion of the Company or its designated person, unless otherwise agreed between the Company and AnchorDx HK.

Save as disclosed above, there is no change to the other major terms of the Transaction Agreement.

By Order of the Board  
**Kindstar Globalgene Technology, Inc.**  
康聖環球基因技術有限公司  
**HUANG Shiang**  
*Chairman*

Hong Kong, January 24, 2025

*As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei and Ms. HUANG Lu as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping and Mr. GU Huaming as independent non-executive Directors.*